sb773812
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2004 (NCT00197093)
Timeline
Indications
Studied for
Mechanism of action
- Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
- Dopamine D2 receptorANTAGONIST
DRD2 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc2c(cc1S(=O)(=O)c1ccc(OCc3ccc(Cl)cc3)cc1)CCN(C)CC2- Mol. weight
- 472.01 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314394 ↗
- ChEMBLCHEMBL3545102 ↗
Also known as
- gw773812
- sb773812
- sb-773812
- sb-773812
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00500201 | Phase 1 | May 1, 2007 | GlaxoSmithKline |
| NCT00411866 | Phase 1 | Oct 1, 2006 | GlaxoSmithKline |
| NCT00259870 | Phase 2 | Sep 1, 2005 | GlaxoSmithKline |
| NCT00269035 | Phase 1 | Jun 1, 2005 | GlaxoSmithKline |
| NCT00197093 | Phase 1 | Sep 1, 2004 | GlaxoSmithKline |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 5 | 5 | 2 | 2004 |
1 organizations
Page 1 / 1